Get the Stockscreener App
0.7706
2.46%
-0.0194
Salarius Pharmaceuticals Inc stock is traded at $0.7706, with a volume of 14,683.
It is down -2.46% in the last 24 hours and up +8.54% over the past month.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
See More
Previous Close:
$0.79
Open:
$0.787
24h Volume:
14,683
Relative Volume:
0.07
Market Cap:
$1.66M
Revenue:
$4.70M
Net Income/Loss:
$-4.99M
P/E Ratio:
-0.12
EPS:
-6.42
Net Cash Flow:
$-5.29M
1W Performance:
+0.01%
1M Performance:
+8.54%
6M Performance:
-46.11%
1Y Performance:
-79.13%
1-Day Range:
$0.7656
$0.787
1-Week Range:
$0.761
$0.8399
52-Week Range:
$0.4519
$7.20
Salarius Pharmaceuticals Inc Stock (SLRX) Company Profile
Name
Salarius Pharmaceuticals Inc
Sector
Industry
Phone
346-772-0346
Address
2450 HOLCOMBE BLVD, HOUSTON
Compare SLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLRX
Salarius Pharmaceuticals Inc
|
0.78 | 1.65M | 4.70M | -4.99M | -5.29M | -6.42 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.52 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.52 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.05 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Salarius Pharmaceuticals Inc Stock (SLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-20 | Initiated | Ladenburg Thalmann | Buy |
Salarius Pharmaceuticals Inc Stock (SLRX) Latest News
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight - GlobeNewswire Inc.
Salarius: Q1 Earnings Snapshot - New Haven Register
Salarius Pharmaceuticals (NASDAQ:SLRX) Trading Up 2.1% – Here’s Why - Defense World
Financial Analysis: Hepion Pharmaceuticals (NASDAQ:HEPA) versus Salarius Pharmaceuticals (NASDAQ:SLRX) - Defense World
Closing Figures Unveiled: Salarius Pharmaceuticals Inc (SLRX) Drop -26.34, Closes at 0.60 - DWinneX
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches By Investing.com - Investing.com Canada
Salarius Pharmaceuticals faces Nasdaq delisting over rule breaches - Investing.com
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Robert S. Langer To Scientific Advisory Board - citybiz
Decoy Therapeutics to Welcome MIT's Robert Langer to Advisory Board Post-Merger with Salarius (SLRX) | SLRX Stock News - GuruFocus
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board - The Manila Times
Moderna Co-Founder and MIT Legend Strengthens Decoy Therapeutics Drug Development Team - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
SLRX stock touches 52-week low at $0.7 amid sharp annual decline - Investing.com Canada
SLRX stock touches 52-week low at $0.7 amid sharp annual decline By Investing.com - Investing.com South Africa
Contrasting Salarius Pharmaceuticals (NASDAQ:SLRX) & ASLAN Pharmaceuticals (NASDAQ:ASLN) - Defense World
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue By Investing.com - Investing.com India
Salarius Amends Merger Terms, Faces Nasdaq Compliance Issue - Investing.com
Decoy Therapeutics’ antiviral candidates show broad activity against multiple viruses - BioWorld MedTech
SLRX stock touches 52-week low at $0.83 amid market challenges By Investing.com - Investing.com South Africa
SLRX stock touches 52-week low at $0.83 amid market challenges - Investing.com Australia
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses - MarketScreener
Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses - GlobeNewswire
Revolutionary AI Platform Discovers Multi-Target Antiviral in Just 5 Days - Stock Titan
Salarius Pharmaceuticals Advances Merger with Decoy Therapeutics to Enhance Development of Innovative Cancer and Viral Therapeutics - Nasdaq
Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update - GlobeNewswire
Salarius Pharmaceuticals Inc. (SLRX) reports earnings - Quartz
Salarius Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Apraxia Treatment Market Size in 7MM is expected to grow at - openPR.com
Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update - Defense World
SLRX stock touches 52-week low at $0.9 amid market challenges - Investing.com
SLRX stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals announces registered share offering - Investing.com
SLRX stock touches 52-week low at $1.22 amid market challenges - Investing.com Australia
SLRX stock touches 52-week low at $1.22 amid market challenges By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals Inc to Host Earnings Call - ACCESS Newswire
Salarius Pharmaceuticals (NASDAQ:SLRX) Shares Up 0.5% – Still a Buy? - Defense World
What Recent Market Trends Mean for Salarius Pharmaceuticals Inc’s (SLRX) Stock - The News Heater
Salarius Pharmaceuticals Inc Stock (SLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):